Clinical and positron emission tomography responses to long-term high-dose interferon-α treatment among patients with Erdheim–Chester disease

BACKGROUND: Erdheim–Chester disease (ECD) is a rare multi-systemic form of histiocytosis. Treatment with BRAF inhibitors has markedly improved outcomes of ECD; however, this targeted therapy is expensive (estimated annual cost is $50,000). Since estimated annual cost of interferon-α (IFN-α) is only...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Xin-xin, Niu, Na, Sun, Jian, Cai, Hao, Wang, Feng-dan, Wang, Yi-ning, Duan, Ming-hui, Zhou, Dao-bin, Li, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327591/
https://www.ncbi.nlm.nih.gov/pubmed/30630516
http://dx.doi.org/10.1186/s13023-018-0988-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327591/
https://www.ncbi.nlm.nih.gov/pubmed/30630516
http://dx.doi.org/10.1186/s13023-018-0988-y

Ejemplares similares